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Increased interferon (IFN)- signaling in patients with insuf-
ficient coronary collateralization and an inhibitory effect of
IFN on collateral artery growth in mice have been reported.
The mechanisms of IFN-induced inhibition of arteriogenesis
are unknown. In stimulated monocytes from patients with
chronic total coronary artery occlusion and decreased arterio-
genic response, whole genome expression analysis showed in-
creased expression of IFN-regulated genes. Immunohisto-
chemically, the IFN receptor was localized in the vascular
media of murine collateral arteries. Treatment of vascular
smooth muscle cells (VSMC) with IFN resulted in an attenu-
ated proliferation, cell-cycle arrest, and increased expression of
cyclin-dependent kinase inhibitor-1A (p21). The growth inhib-
itory effect of IFNwas attenuated by inhibition of p21 by RNA
interference. IFN-treated THP1monocytes showed enhanced
apoptosis. Subsequently, we tested if collateral artery growth
can be stimulated by inhibition of IFN-signaling. RNA inter-
ference of the IFN receptor-1 (IFNAR1) increased VSMC
proliferation, cell cycle progression, and reduced p21 gene
expression. IFN signaling andFASandTRAIL expressionwere
attenuated in monocytes from IFNAR1/ mice, indicating
reduced monocyte apoptosis. Hindlimb perfusion restoration 1
week after femoral artery ligation was improved in IFNAR1/
mice compared with wild-type mice as assessed by infusion of
fluorescentmicrospheres. These results demonstrate that IFN
inhibits collateral artery growth and VSMC proliferation
throughp21-dependent cell cycle arrest and induction ofmono-
cyte apoptosis. Inhibition of IFN stimulates VSMC prolifera-
tion and collateral artery growth.
Collateral arteries alleviate symptoms of ischemia in pa-
tients with arterial obstructive disease. Circulating mono-
cytes play an essential role in the growth of collateral arteries
(1). We recently performed a monocyte mRNA expression
study in patients with single vessel subtotal coronary artery ste-
nosis. Genome-wide expression analysis demonstrated that
increased expression of interferon (IFN)2- as well as IFN
downstream genes is associated with insufficient coronary col-
lateral artery growth, suggesting a potential anti-arteriogenic
effect of this glycoprotein. In a murine model, application of
IFN indeed resulted in an attenuated arteriogenic response
upon femoral artery occlusion (2).
In the current study, we investigated gene expression profiles
of stimulated monocytes from patients with chronic total cor-
onary occlusions. In contrast to patients with subtotal occlu-
sions as previously studied, these patients can be considered to
be in a stable phase of collateralization inwhich collateral artery
growth has been maximally triggered and has reached its pla-
teau phase.
The mechanisms via which IFN exerts its anti-arterio-
genic effects are unresolved. It is hitherto unknown if inhi-
bition of IFN signaling results in stimulation of collateral
artery growth. Vascular smooth muscle cells (VSMC) display a
high rate of proliferation during arteriogenesis (3). In growing
arteriolar anastomoses, they change froma contractile toward a
proliferative phenotype (4). We therefore analyzed the effects
of IFN application and inhibition in in vitromodels of VSMC
cell cycling and proliferation and on monocyte apoptosis. In
vivo, the effects of inhibition of IFN were tested in mice lack-
ing the subunit 1 of the IFN/ receptor (IFNAR1/mice) (5).
MATERIALS ANDMETHODS
Patient Study—The investigation conforms to the princi-
ples outlined in the Declaration of Helsinki and was ap-
proved by the institutional medical ethics committee (Ref.
no. MEC 06/186). After giving informed consent, 50 Cauca-
sian patients were included who underwent percutaneous
coronary intervention (PCI) of a total coronary occlusion.
Patients were considered eligible if they had symptoms of
angina pectoris for 4 weeks and total chronic occlusion
(CTO) of a coronary artery. Exclusion criteria were previous
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myocardial infarction, cardiac surgery, depressed left ventricu-
lar function, diabetes mellitus, neoplastic, or inflammatory dis-
ease. Invasive coronary collateral flow index (CFI) measure-
ments were performed as previously described (2). Briefly, a
0.014 inch pressure guide wire (BrightWire, Volcano, Rancho
Cordova, CA) was used for intracoronary pressure measure-
ments. During a 1-min balloon inflation, the pressure distal to
the coronary occlusion (wedge pressure, Pw) as well as aortic
(Pao) pressure was determined. CFI was calculated as (Pw-
CVP)/(Pao-CVP), where CVP was estimated to be 5 mmHg.
Mononuclear cells were collected from peripheral blood by
density gradient centrifugation. Monocytes were negatively
isolated using immunomagnetic beads and stimulated in cul-
ture with 10 ng/ml LPS for 3 h.mRNA frommonocytes from 10
and 10 patients from the extreme ends of the spectrum (very
high versus very low CFI and matched for age, sex, medication,
and other factors that influence collateral artery growth), was
amplified and biotinylated. Samples were randomly hybridized
to HumanRef-8 Expression bead chip arrays (Illumina), fol-
lowed by scanning and feature extraction, all performed at Ser-
viceXS (Leiden, The Netherlands). Microarray data have been
submitted to the Gene Expression Omnibus (GEO) under
accession number GSE13290.
Validation of Gene Array Results—RNA from all 50 patients
was reverse-transcribed into cDNA, and gene expression of
CXCL9, CXCL10, CXCL11, CCL8, IL27, IFIT1, IL15RA, and
GAPDH was assessed using real-time RT-PCR.
Animal Experiments—The investigation was approved by
the Institutional Medical Ethics Committee (Ref. no. DKC
100847) and conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIHPublicationNo. 85–23, revised 1996). 30wild-type
(129Sv/Ev) and 20 IFN/-receptor-1 knock-out (IFNAR1/)
mice underwent unilateral double femoral artery ligation. Ten
wild-type mice received daily subcutaneous injections of 105
IU/kg rmIFN.
Gene and Protein Expression Analysis of Murine Monocytes
andHindlimb Tissue—Three days after femoral artery ligation,
blood was collected using cardiac puncture, and peripheral
blood monocytes were isolated by density gradient centrifuga-
tion, taking the mononuclear cell fraction into culture for 2 h
and washing away non-adherent cells. Adhering monocytes
were subsequently stimulated with 10 ng/ml lipopolysaccha-
ride (LPS) for 3 h. Monocyte gene expression was assessed by
FIGURE 1. Differential interferon response between patients with low
andhighCFI.MicroarraymRNA expression levels of interferon related signa-
ture genes in stimulatedmonocytes of patients with low (gray bars) and high
(black bars set to 1) CFI. The bar graphs compare the average relative mRNA
levels of n 55 interferon-related genes. Note that these 55 signature genes
have an elevated expression level in patients with low CFI, as determined by
GSEA. A, gene symbol marked with an asterisk indicates the presence of an
inter-species conserved IRF-1 or -2 motif within the promoter region of that
gene as determined by GSEA or rVISTA.
TABLE 1
Gene set enrichment analysis: interferon target sets in patients with
low versus high CFI
The depicted gene sets are enriched in patients with low CFI and result from two
separateGSEA comparing the transcriptomes of patientswith either low (n 10) or
high (n 10) CFI. We used gene sets consisting of (A) 1892 curated pathways from
various sources and (B) 500 transcription factor binding sites defined in the
TRANSFAC database, version 7.4. These sets are available online at the BROAD
Institute (10). See supplemental Table S3 for a complete overview of publications on
which these interferon target gene sets are based.
Sets (n) GSEA statisticsNESa FDRb FWERc
% %
A. IFN target set
type II 2 2.5 0 0
type I 5 2.6 0 1
I and II 2 2.1 0 7
B. Transcription factor
IRF2 1 1.8 3 11
IRF3 2 1.9 2 15
IRF1 1 1.8 7 33
IRF 1 1.7 7 40
IRF8 1 1.7 6 41
aNES, normalized enrichment score.
b FDR, false discovery rate.
c FWER, family wise error rate.
TABLE 2
Real-time RT-PCR from all 50 CTO patients analysis confirms the
consistent up-regulation of a panel of IFN target genes in patients
with low CFI
Results are depicted as fold-changes of patients with low compared to high CFI.
Gene expression of CCL8, CXCL11, IL27, and IL15RA significantly correlated
inversely with CFI.
Symbol -Fold change p value for-fold change
Correlation
coefficient
p value
for correlation
CCL8 1.53 0.093 0.371 0.010
CXCL9 1.44 0.086 0.218 0.137
CXCL10 1.25 0.298 0.169 0.252
CXCL11 1.45 0.020 0.353 0.014
IL27 1.34 0.046 0.355 0.013
IFIT1 1.37 0.055 0.259 0.075
IL15RA 1.31 0.043 0.353 0.014
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real-time RT-PCR of mm8S rRNA, mmIFNAR1, mmSTAT1,
mmCXCL10, mmCXCL11, mmIL15, mmTNFSF10, mmFASL,
mmFAS, and mmCASP7.
Hindlimb was dissected for RNA and protein isolation. Gene
expression was analyzed by real-time RT-PCR of the following
targets: mm18SrRNA, mmIFNAR1, mmIRF3, mmSTAT1,
mmCXCL10,mmCXCL11mIL15,mmTNFSF10, andp21. Pro-
tein content was measured spectroscopically. ELISA analysis
for murine CXCL10 was performed from isolated protein.
Immunohistochemical Analysis of Hindlimb Tissue—Seven
days after femoral artery ligation, hindlimb tissuewas dissected,
and frozen sections were prepared
and stained with a monoclonal goat
anti-mouse IFNAR1 antibody for its
localization in growing collateral
arteries. VSMCwere visualizedwith
an antibody against -smooth mus-
cle actin (Sigma), nuclei stained
with Hoechst 33342 (Molecular
Probes).
Hindlimb Perfusion Measure-
ments—Seven days after femoral
artery ligation, perfusion restora-
tion was assessed using fluorescent
microsphere infusion under condi-
tions of maximal vasodilation by
infusion of adenosine in an estab-
lished mouse model of arteriogen-
esis as previously described (6).
Hindlimb tissue was harvested,
digested, and microspheres were
counted in a flow cytometer. Perfu-
sion restoration was expressed as
percentage perfusion ligated versus
non-ligated hindlimb.
In Vitro Analysis of Monocyte
Apoptosis and Gene Expression
uponIFNTreatment—THP-1mono-
cytes (ATCC) were treated with
increasing concentrations of rhIFN,
and apoptosis was measured after
24 and 48 h by staining with
Annexin V and propidium iodine
(PI) antibodies and detecting the
percentage of Annexin V-positive
PI-negative cells using flow cyto-
metry. IFN-stimulated THP-1
monocytes also underwent gene
expression analysis of P0, CXCL11,
p15, p21, p27, FAS, FASL, and
TNFSF10. Similarly, freshly isolated
primary human monocytes from
health donors were stimulated with
IFN andunderwent geneexpression
analysis of P0,CXCL11, p21, andFAS
as well as measurement of apoptosis.
In Vitro Analysis of VSMC Prolif-
eration and Gene Expression—Fol-
lowing stimulation with IFN, gene expression of CXCL10 and
IL15 was assessed in VSMC using real-time RT-PCR. Expres-
sion of STAT1 protein was assessed in VSMC using Western
blot.
Proliferation of primary human VSMC was assessed in
vitro by determining their BrdU-uptake after stimulation
with rhIFN, rhCXCL10, or rhIL15. Cell cycle analysis was
performed by flow cytometric analysis of cellular DNA content
after staining with propidium iodine.
To investigate whether the effects of IFN on VSMC are
depending on p21, VSMCwere transfected with siRNA against
FIGURE 2. IFN induces apoptosis in THP1 monocytes in vitro. Percentage of apoptotic THP1 monocytes
dose-dependently increased (A), with a greater effect after 48 h than after 24 h of stimulation with IFN.
Increased gene expression of CXCL11 confirmed enhanced IFN signaling (B). TRAIL, FAS, and FASL (C–E) were
up-regulated, supporting the anti-proliferative and pro-apoptotic effect of IFN onmonocytes. Expression of
cyclin-dependent kinase inhibitor 1A (p21)was found up-regulated upon IFN stimulation (F), indicating a cell
cycle inhibiting effect of the cytokine. p15 and p27 were not significantly differentially expressed (G, H). In
primary human monocytes, IFN similarly induced apoptosis (I) and increased expression of CXCL11 (J), FAS
(K), and p21 (L). *, p 0.05; **, p 0.01; ***, p 0.001 compared with 0 ng/ml IFN.
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p21. As a control, nonspecific siRNA was used. Expression of
p21 and IFN target genes were measured at gene (real-time
RT-PCR) and protein levels (Western blot), and proliferation
and cell cycle were assessed as above.
Inhibiting IFN signaling in vitro, VSMCs were also trans-
fected with siRNA against the IFN/ receptor-1 (IFNAR1) or
nonspecific siRNA. Down-regulation of IFNAR1 was assessed
at mRNA (real-time RT-PCR) and protein level (Western blot).
Proliferation and cell cycle status
was assessed as described above,
and gene expression of P0, IFNAR1,
CXCL10, IL15, p15, p21, and p27
was analyzed.
Statistical Analysis—In vitro and
animal data arepresented asmeans
S.E. of the mean. Intergroup com-
parisons were performed using
Student’s t test if normally distrib-
uted. Comparisons between three
or more groups were performed us-
ing one-way analysis of variance
(ANOVA) and Bonferroni post-hoc
correction. Dose-dependent trends
were calculated using probit regres-
sion analysis. A p value 0.05 was
considered statistically significant.
Normalization and statistical analy-
sis of the gene array data were car-
ried out using the limmapackage (7)
and scripts in R/Bioconductor (8).
Genes were considered significant if
the p values, adjusted for multiple
testing by using Benjamini and
Hochberg’smethod (9), were0.05.
The false discovery rate was thereby
controlled to be 5%. Gene set
enrichment analysis (GSEA) (10)
was used for analysis of differential
expression of functional groups of
genes and their promoters (c2,
curated gene sets; c3, transcription
factor targets, TRANSFAC version
7.4), employing MSigDB version
2.5. See supplemental data for a
detailed description of themethods.
RESULTS
Expression of IFN-regulated Genes
Is Increased in Patients with Ham-
pered Collateral Artery Growth—
Whole-genome expression of
LPS-stimulated monocytes from
patients with CTO was analyzed in
relation to the capacity of the coro-
nary collateral circulation. 10 pa-
tients with lowest CFI (0.27  0.06)
were compared with 10 patients
with highest CFI (0.47 0.08), who
were well matched for factors potentially influencing collater-
alization (supplemental Table S1). After correcting formultiple
testing, 120 genes were found to be differentially expressed
between patientswith low and highCFI, of which 65 geneswere
more strongly induced in the group with a low CFI. Pathway
analysis (GSEA) showed a highly significant enrichment of sev-
eral interferon-related pathways in patients with a low CFI
(Table 1). Individual genes of these pathwayswere up-regulated
FIGURE 3. IFN attenuates proliferation of VSMC in vitro. Immunohistochemistry showed expression of
IFNAR1 (red) in the collateral arterialmedia (VSMC,green, nuclei,blue) (A). IFN treatmentup-regulatedCXCL10
and IL15 (B, C) at gene level and STAT1 at protein level (D). Application of either of either CXCL10 or IL15 to
VSMC in vitro remainedwithout an effect on proliferation, asmeasured by BrdUuptake (E, F). Cell cycle analysis
showed increased cell numbers arrested in G-phase and reduced cell in S-phase after treatment with IFN
(*, p 0.05 for dose-dependent trends) (G), and p21 expression was enhanced by IFN treatment (H). *, p
0.05; **, p 0.01 compared with 0 ng/ml IFN.
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(Fig. 1), and analysis of their promoter sequences confirmed the
strong enrichment for IFN response elements (Table 1).
GSEA core-enrichment of the individual genes within these
gene sets is shown in supplemental Table S2. Results of the
GSEA transcriptome comparison of patients with low and high
CFI were projected onto the LPS-induced TLR4 pathway, visu-
alizing the enhanced activation of specifically the IFN path-
way in patientswith a lowCFI (supplemental Fig. S1). Real-time
RT-PCR analysis of thewhole patient group (n 50) confirmed
increased expression of IFN-regulated genes in stimulated
monocytes from patients with low CFI. Negative correlations
with CFI were found for gene expression of the IFN-regulated
genes CXCL11, CCL8, IL27, and IL15RA (Table 2). Dichoto-
mizing patients according to the median CFI detected in the
whole group (0.37), fold-changes between low and high CFI
were calculated. Individual gene fold-changes were low, but the
consistent and coordinated up-regulation of the panel of IFN
genes confirmed the GSEA pathway analysis results.
IFN Treatment Induces TRAIL and p21 in Vivo—To inves-
tigate the mechanisms of IFN-induced inhibition of collateral
artery growth, a murine hind limbmodel of femoral artery liga-
tion was employed. In collateral-containing hindlimb tissue
from IFN-treated mice, gene expression of pro-apoptotic
TNF-related apoptosis-inducing ligand (TRAIL), previously
shown to mediate IFN-induced apoptosis in lymphoma cells
(11), and anti-proliferative IL15 (12) were increased compared
with control group (TRAIL: 17.22  2.62 versus 7.33  0.93,
p  0.01; IL15: 38.97  6.13 versus 10.29  1.04, p  0.001).
IFN-treated mice also displayed enhanced expression of
the cell cycle regulator cyclin-dependent kinase inhibitor-1A
(CDKN1, p21), known to negatively regulate G1- to S-phase
transition (59.49 12.50 versus 7.37 1.65, p 0.01).
IFN Induces Apoptosis of Monocytes in Vitro—To analyze
its effects on mononuclear cells, THP1 cells were treated with
increasing concentrations of IFN. FACS analysis showed
enhanced apoptosis after 24 h and after 48 h exposure (4.6 ver-
sus 38.1% apoptosis after 48 h stimulation with 0 versus 100
ng/ml IFN, Fig. 2A). Real-time RT-PCR for CXCL11 con-
firmed increased IFN signaling (Fig. 2B). TRAIL, FAS, and
FASL were found up-regulated upon stimulation with IFN,
indicating cell death signaling (Fig. 2, C–E). IFN stimulated
expression of p21 but not p15 or p27 (Fig. 2, F–H).
To confirm the effects of IFN on THP1 cells in primary
cells, the experiments were repeated in freshly isolated human
monocytes. Comparable to THP1 cells, IFN dose-depen-
dently induced apoptosis after 48 h incubation (27.7%  5.2
versus 10.4  1.2 apoptotic cells, Fig. 2I) and increased gene
expression of CXCL11, FAS, and p21 (Fig. 2, J–L).
IFN Attenuates Proliferation of VSMC via Cell Cycle Arrest—
Immunohistochemistry showed expression of the type I inter-
feron-receptor IFNAR1 in the vascular media of collateral
arteries (Fig. 3A). IFN has been shown to inhibit VSMC pro-
liferation in vitro (2). As demonstrated by real-time RT-PCR,
IFN treatment up-regulated gene expression of the anti-an-
giogenic factors CXCL10 and IL15 as downstream targets of
IFN in VSMC (Fig. 3, B and C). Also, STAT1 was increased at
protein level (Fig. 3D). However, application of increasing doses
of recombinant human CXCL10 and IL15 did not affect VSMC
proliferation as measured by BrdU incorporation (Fig. 3, E and
F). Instead, cell cycle analysis showed increased percentages of
cells arrested in the G1 phase of the cell cycle after IFN treat-
ment (97.8 versus 66.7% for 100 versus 0 ng/ml IFN, Fig. 3G),
and p21 gene expression was found to be up-regulated, already
at low concentrations of IFN (Fig. 3H). Expression of two
other cell cycle regulators p15 and p27 were not affected by
IFN (data not shown).
VSMC Cell Cycle Inhibition of IFN Is Mediated by p21—
Subsequently, we tested if IFN-induced VSMC cell cycle
inhibition was dependent on p21. Using RNA-interference,
p21 protein expression was attenuated in VSMC in vitro.
Whereas expression of p21 protein was induced at low con-
centrations of IFN (1 ng/ml), this effect was abolished by
previous siRNA treatment against p21. BrdU incorporation
experiments confirmed the anti-proliferative effect of IFN,
which was abrogated by anti-p21 siRNA. Accordingly, anti-
p21 treatment reversed the cell cycle inhibiting effect of
IFN. See also Fig. 4.
InVitro Blockade of IFN Signaling Leads to IncreasedVSMC
Proliferation—Having found that IFN attenuates VSMC pro-
liferation via its effects on cell cycle regulation, we next hypoth-
esized that inhibition of IFN signaling could stimulate VSMC
proliferation. In VSMC in vitro, IFNAR1 gene (RT-PCR) and
protein expression (Western blot) were found down-regulated
after transfection with siRNA (Fig. 5, A and B). After 48 h of
transfection, BrdU incorporationwas increased inVSMC, indi-
cating enhanced proliferation in these cells (Fig. 5C). Cell cycle
analysis indicated increased cell numbers in S-phase in IFNAR1
siRNA compared with control siRNA-transfected cells (35.8
versus 54.2%, Fig. 5D). Concomitantly, p21 expression was
FIGURE 4. Cell cycle-inhibiting effect of IFN is dependent on p21. siRNA
against cell-cycle inhibitor p21 dose-dependently reduced p21 protein
expression in VSMCas comparedwith nonspecific control-siRNA (A). p21 pro-
tein expression is stimulated by IFN (compare gene expression Fig. 3H). This
up-regulation is attenuated after preincubation with p21 siRNA (B). BrdU
incorporation analysis confirmed the anti-proliferative effect of IFN, which
was abrogated by pretreatment with p21 siRNA (C). Similarly, the cell cycle-
arresting effect of IFN is attenuated by inhibiting p21 (D). Interestingly, p21
siRNAeven increased cell cycling in thepresenceof IFN (enhancednumbers
of cells in S phase, less in G1 phase). *, p 0.05 compared with 0 ng/ml IFN;
#, p 0.05 compared with same concentration IFN, ctrl siRNA.
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reduced in VSMC treated with IFNAR1 siRNA compared with
nonspecific siRNA (Fig. 5E).
Arteriogenesis Is Increased in IFNAR1/ Mice—Finally,
we tested whether blocking IFN signaling stimulates arte-
riogenesis in vivo. Using microsphere infusion at different
pressure levels under conditions of maximum vasodilation 1
week after femoral artery ligation
we calculated hindlimb perfusion
per gram tissue. Perfusion restora-
tion (ligated versus non-ligated
hindlimb) was found improved in
IFNAR1/ mice compared with
control group (54.3  2.5% versus
38.3  2.7%, p  0.001, Fig. 6).
Gene Expression of Stimulated Cir-
culating Monocytes of IFNAR1/
Mice Is Comparable to Patients
with Well-developed Collateral Ar-
teries—To mimic the activation
status of monocytes in the clini-
cal situation, murine circulating
mononuclear cells were stimu-
lated with LPS ex vivo. Real-time
RT-PCR showed strongly reduced
expression of IFNAR1, STAT1,
CXCL10, CXCL11, TRAIL, and
IL15 as signs of abrogated IFN sig-
naling in LPS-stimulated mono-
cytes of IFNAR1/ compared with
wild-type mice (Fig. 7, A–F), result-
ing in an expression profile compa-
rable to that of stimulated mono-
cytes from patients with a good
collateralization. Apoptosis related
molecules FASL, FAS, and CASP7
were also found reduced (Fig. 7,
G–I).
Reduced Expression of IFN Targets
in Collateral-containing Hindlimb
Tissue of IFNAR1/ Mice—Gene
expression analysis of collateral-
containing tissue showed reduced
mRNA expression of the IFN
pathway in the IFNAR1/ mice.
IRF3, CXCL10, STAT1, CXCL11, and IL15 were found
decreased compared with control animals (Fig. 8, A–F). At the
protein level, ELISA analysis showed reduced expression of
IFN downstream cytokine CXCL10 in IFNAR1/ mice
(5.2 1.8 versus 54.5 8.9 relative to total protein (Fig. 8G).
DISCUSSION
IFN signaling was enhanced in stimulated monocytes
from patients with chronic total coronary artery occlusion
and hampered coronary collateralization. In vitro, IFN
exerted a direct pro-apoptotic effect on monocytes. Prolifer-
ation analysis showed a p21-dependent inhibiting effect of
IFN on VSMC, which were arrested in the G1-phase.
Knockdown of IFNAR1 had the opposite effect, resulting in
an increased number of VSMC in the S-phase and enhanced
proliferation. Finally, we report decreased IFN- and apo-
ptosis-related gene expression as well as increased collateral
artery growth in IFNAR1/ mice, showing that inhibition
of IFN signaling augments arteriogenesis.
FIGURE 5. Blockade of IFN signaling leads to increased VSMC proliferation in vitro. Real-time RT-PCR (A)
andWestern blot (B) confirmed strongly reduced expression of IFNAR1 in VSMC transfectedwith siRNAagainst
IFNAR1as comparedwith cells transfectedwithnonspecific control siRNA. Proliferationwasenhanced inVSMC
in which IFNAR1 was knocked down (C). Cell cycle analysis showed increased progression to S-phase in siIF-
NAR1-treated cells (D). IFNAR1 knockdown resulted in decreased mRNA expression of the cell cycle inhibitor
p21 (E). *, p 0.05; **, p 0.01 compared with control siRNA.
FIGURE 6.Arteriogenesis is enhanced in IFNAR1/mice.Hindlimb per-
fusion was assessed 1 week after femoral artery ligation using infusion of
fluorescent microspheres under conditions of maximal vasodilation (n 
10). Perfusion restoration, expressed as percentage ligated versus non-
ligated hindlimb, was increased in IFNAR1/ compared with wild-type
mice (***, p  0.001).
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Following our earlier study on IFN signaling and collat-
eral artery growth (2), we here confirmed increased IFN
signaling in an independent patient population (Fig. 1). In
patients with CTO, the driving forces of arteriogenesis are
less variable because the stenosis grade of the original coro-
nary artery is constant (i.e. 100%). CFI measurements are
therefore less susceptible to interindividual variations of
coronary baseline hemodynamics. Besides, the present data
demonstrate that increased IFN signaling is also found in
patients with a low arteriogenic response despite the pres-
ence of a chronic total coronary occlusion, where collateral
artery growth has reached a plateau phase. Despite this max-
imal response, a large number of patients remain sympto-
matic indicating a need for further growth of coronary col-
lateral arteries.
Subsequently, in vitro and animal experiments were em-
ployed to disclose the mechanisms of the anti-arterioge-
nic effect of IFN. Because the IFN receptor was detected
in the vascular media, effects of its stimulation and block-
ade were investigated in VSMC in vitro (Fig. 3). We report
that IFN exerts its negative effects on VSMC proliferation
by inducing cell cycle arrest in a
p21-dependent fashion (Fig. 4).
The cell cycle regulator p21 is
known as the major mediator of
cell cycle arrest (13). Its regulation
by IFN has previously been
observed in tumor cells (14), and
inhibition of p21 has been shown
to regulate endothelial cell pro-
liferation (15). Antiproliferative,
pro-apoptotic effects of IFN are
known in oncology but have not
yet been examined in cardiovascu-
lar pathophysiology. p21-medi-
ated cell cycle inhibition by IFN
has not been described previously
in VSMC (16).
The inhibitory effect of IFN on
endothelial cell sprouting (angio-
genesis) is mediated by CXCL10
(17). Its influence on collateral
artery growth has not been studied.
Our data show that the anti-arterio-
genic effect of IFN is not mediated
by CXCL10, because IFN but not
CXCL10 inhibited VSMC prolifera-
tion (Fig. 3).
We reasoned that inhibition of
IFN signaling might stimulate
VSMC proliferation and arterio-
genesis. Reduction of p21 expres-
sion and VSMC cell cycling and
proliferation upon inhibition of
IFN signaling showed that inhibi-
tion of cytokine signaling can stim-
ulate cell growth (Fig. 5). Vascular
regeneration has hitherto been
linked to increased inflammatory signaling. For the first time,
we show that reduced cytokine signaling can also stimulate
arterial growth.
As anti-IFN treatment stimulated cellular proliferation
in vitro, we hypothesized that a blockade of IFN signal-
ing may boost adaptive collateral artery growth in vivo. In a
first approach, treatment with IFN neutralizing antibodies
showed no effect on perfusion restoration (data not shown).
Subsequent in vitromeasurements indicated that concentra-
tions of 5,000 IU/ml of IFN neutralizing or anti-IFNAR1
antibody were necessary to accomplish a 50% blockade of
IFN signaling. Achieving these concentrations in vivo
would have resulted in unfeasibly high costs. We therefore
decided to use a murine knock-out model of the interferon
/ receptor. In IFNAR1/ mice, a neo-marker is inserted
in Exon III, resulting in dysfunctional mRNA and a loss of
functional receptor protein (5). Because the promoter of the
IFNAR gene is intact, mRNA is still detectable.3 This is
3 U. Mu¨ller, personal communication.
FIGURE 7. Inhibition of IFN- and apoptosis signaling in stimulated monocytes of IFNAR1/ mice. In
LPS-stimulatedmonocytes from IFNAR1/mice, expression of IFNAR1, signalingmolecule STAT1 and target
genes CXCXL10 and CXCL11 was strongly suppressed compared with wild-type mice (A–D). TRAIL and IL15,
both part of the IFN signaling cascade,were strongly down-regulated in stimulatedmonocytes of IFNAR1/
mice (E, F), as were apoptosis-related molecules FAS, FASL, and CASP7 (G–I). *, p 0.05; **, p 0.01; ***, p
0.001 compared with wild-type mice.
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reflected by our real-time RT-PCR data, showing decreased
but still existent IFNAR mRNA in monocytes from
IFNAR1/ mice. Interestingly, concerning the IFN path-
way, gene expression profile of the stimulated murine mono-
cytes and collateral-containing hindlimb tissue of IFNAR1/
mice was comparable to that of stimulated monocytes from
patients with high CFI (Fig. 7).
Both gene expression data from murine monocytes and
functional assays in vitro indicate increased monocyte apo-
ptosis upon simulation with IFN. Increased apoptosis sig-
naling pathways were also found in patients with low CFI.
Our data (Fig. 2) corroborate earlier reports on IFN-medi-
ated induction of apoptosis in monocytes from patients with
multiple sclerosis (18). IFN has previously been demon-
strated to induce up-regulation of surface-bound TRAIL and
release of soluble TRAIL in human monocytes (19), and
IFN-induced apoptosis has been reported to be mediated
by TRAIL in lymphoma cells (11). Regulation of apoptosis by
p21 through its caspase-mediated cleavage from cyclin-de-
pendent kinase 2 has been described in endothelial cells (20).
Decreased apoptosis-related gene expression in monocytes
from IFNAR1/ mice suggests reduced susceptibility for
programmed cell death in these cells.
We here show that inhibition
of IFN signaling can stimulate
cell proliferation in vitro and arte-
riogenesis in vivo. Pro-arteriogenic
substances are mostly cytokines
(growth factors, chemoattractants
or colony-stimulating factors) which
have pro-inflammatory or bone-
marrow cell releasing effects, both
of which potentially aggravate ath-
erosclerosis or destabilize plaques
(21). Recent data suggest that IFN
attenuates angiotensin II-induced
atherosclerosis in ApoE/ mice,
while IFN alone did not have any
effect on atherosclerosis in that
study (22). Another study showed
aggravation of atherosclerosis by
myeloid type I IFN (23). These con-
flicting data require further study
when considering anti-IFN ther-
apy for the promotion of arteriogen-
esis. Therapeutic inhibition of inter-
ferons to promote blood vessel
growth could also activate autoim-
mune processes, which are nor-
mally inhibited by IFN, as has been
discussed earlier (24).
We conclude that inhibition of
IFN signaling might serve as an
approach to stimulate collateral
artery growth by stimulating VSMC
proliferation and cell cycling. Fur-
ther investigations of the modula-
tion of IFN signaling using phar-
macological inhibitors of IFN or its receptor are required in
atherosclerotic models before clinical approaches can be
envisaged.
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